|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| Product | |||||
| Service | |||||
| Listing sponsorship services | |||||
| Collaboration revenue | |||||
| Total revenue | |||||
| Operating expenses | |||||
| Cost of products sold | |||||
| Total cost of products sold | |||||
| Cost of services | |||||
| Research and development, net | |||||
| General and administrative | |||||
| Sales and marketing | |||||
| Impairment of right-of-use asset | |||||
| Impairment of property and equipment | |||||
| Impairment expense of goodwill | |||||
| Loss on deconsolidation of subsidiaries | |||||
| Total operating expenses | |||||
| Operating income | |||||
| Interest and other income, net | |||||
| Interest expense | |||||
| Gain on extinguishment of debt | |||||
| Gain on impairment adjustment | |||||
| Gain on settlement of compensation expenses | |||||
| Change in fair value of EIB loan guaranty | |||||
| Foreign currency transaction gains | |||||
| Change in fair value of derivative financial instruments | |||||
| Total other income | |||||
| Income before income taxes | |||||
| Provision for income taxes | |||||
| Net income | |||||
| Deemed dividend on beneficial conversion feature | |||||
| Net income allocated to preferred stockholders - diluted | |||||
| Net income available to common stockholders - diluted | |||||
| Basic | |||||
| Diluted | |||||
| Other comprehensive income - foreign currency translation | |||||
| Comprehensive income | |||||
| Net income allocated to preferred stockholders - basic | |||||
| Net income available to common stockholders - basic | |||||
Loading...